Scrip Watch

Godavari Drugs Ltd

Scrip Sanctuaries for protection from the wildlife in this jungle of Indian Equities

Godavari Drugs Ltd

Godavari Drugs Ltd
Pharmaceuticals
FV – Rs 10; 52wks H/L – 54.9/34; TTQ – 1243; CMP – Rs 42 (As On May 22, 2017);                      

            Market Cap – Rs 32Crs

Standalone Financials and Valuations for FY16 (Amt in Rs Crs unless specified)


Equity Capital

Net worth
Long Term Debt
Total
Sales
PAT
BV
(Rs)

EPS (Rs)

P/E

Industry P/E

P/BV

Promoter’s
Stake
Beta
7.53 15 4 71 1.35 20 1.79 23.46 29.41 2.1 49.91 1.66

 

Standalone Financials and Valuations for 9Mnths FY17


Equity Capital

Net worth
Long Term Debt
Total
Sales
PAT
BV
(Rs)

TTM EPS (Rs)

P/E

Industry P/E

P/BV

Promoter’s
Stake
Beta
7.53 17 4 65 1.22 23 1.62 25.93 29.41 1.83 49.91 1.66

 

 

Valuation Parameters:

  1. Long Term Debt to Equity – 0.3
  2. ROE % – 9
  3. Market Cap/Sales – 0.5

Overview:

  • Godavari Drugs Ltd is engaged in the contract manufacturing, loan license manufacturing, manufacturing and supply of active pharmaceutical ingredients (APIs), drug intermediaries and fine chemicals.
  • The Company’s API products include Ciprofloxacin Hydrochloride, Enrofloxacin, Centrizine Hydrochloride and Ethambutol Hydrochloride.
  • Its intermediate products include A D Lactone and Benzhyryl Piperazine.
  • Its manufacturing facilities are located at Maharashtra Industrial Development Corporation estate at Nanded, Maharashtra, India.
  • The manufacturing facilities are equipped with glass lined reactors, stainless steel reactors, filtration equipment of various types, drying equipment of various types, compaction facilities, solvent recovery and rectification facilities, hydrogenation facilities suitable for high pressures up to 45 bar, vapor phase catalytic tube reactors operable at temperatures in the range of 450 degrees centigrade, distillative reaction facilities and others.

 

Management:

  • Ghanshyam Jaju – Chairman
  • Mukund Kakani – MD
  •  Kirti Kumar Jain – CFO

 

The Equity Capital is @ Rs 7.53 Crs consisting of 7530500 equity Shares of FV Rs 10 currently held as under

10.48% Of the Promoter’s Holding is pledged.

Major Non – Promoter Holdings:

Non – Promoters No. of shares held % of shares held
Kewal Goel 148700 1.97
Pawan Kothari 98198 1.3
Anuradha Karanjgaokar 100000 1.33
Vrunda Karanjgaokar 100000 1.33
Varun Jain 100000 1.33
Ashwini Karanjgaokar 100000 1.33
Karanjgaokar 80000 1.06

 


Standalone Financial Trends (In Rs. Crs) :

Particulars FY16 FY15 FY14 FY13 FY12
Equity Paid Up 7.53 7.53 7.53 7.53 7.53
Networth 15 14 10 8 7
Total Debt 16 9 2 3 2
Net Sales 71 55 9 8 4
Other Income 0.2 0 0 0 0
PAT 1.35 3.85 1.55 0.48 -1.6
Book Value (Rs) 20 19 13 11 9
EPS (Rs) 1.79 5.11 2.06 0.64 -2.12

 

 

 

 

 

Excerpts from Gaurav’s Blog

  Rest in Peace now Gerela Saab  ! Mr S T Gerela ex GM of BSE passed away peacefully this morning We had not met in years but he always remained at the top of my mind when it came to testimonials for this is what he had said to me over a decade ago,when […] [...]

Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal ! Promoter Group of  Vedanta Ltd has proposed a voluntary de-listing at an indicative offer price of Rs 87.50~are the over 7.3 lakh minority shareholders from Alibag !? …apologies to the people of Alibag Some would term this as De-listing Duplicity ~ but I would […] [...]

This is a Riskless Reliance Industries Rights Investment Strategy for those over 2.3 Million Shareholders already holding RIL shares. It is not a recommendation to buy RIL cum rights  It’s a no brainer yet I’m just penning a brief note because some have told me they hold Reliance but are skipping the Rights ! Don’t […] [...]

 Wealth is negotiable, Health is not Your Personal Well Being is more important that the Stock Market Well Being ~ Always & more so in this unfathomable ongoing Covid-19 Reality Above’s a three minute reach out by me last night to all connected with me to reinforce this .It’s also posted on Facebook , […] [...]

Yes Bank ~ Has the RBI & MOF lost it !? SEBI really is a bystander here Controversial Lock In Clause 3 Sub Clause 8 (a) in the Scheme of Reconstruction  No wonder the Finance Minister Mrs Nirmala Sitharaman, while highlighting only selected points, even when asked for details of the Scheme,did not want to […] [...]